The short answer
No. Their drug identifiers and billing increments differ, and product potency units are not a clinical conversion formula. Check the exact product’s HCPCS definition and prescribing information. Never infer an equivalent treatment dose by dividing or multiplying the billing increments.
Build a product-specific charge reference
The CMS article identifies J0585 for onabotulinumtoxinA, J0586 for abobotulinumtoxinA, J0587 for rimabotulinumtoxinB and J0588 for incobotulinumtoxinA. The billing increments differ: respectively 1, 5, 100 and 1 product units. This is a selected reference, not an exhaustive current code set.
Separate coding from prescribing
BOTOX prescribing information states that its potency units are specific to the product and assay and are not interchangeable with other toxin preparations. A billing worksheet must not double as a treatment conversion chart. Product substitutions require clinical review and a fresh billing check.
Your practical checklist
- Match brand and nonproprietary name to the actual package.
- Verify the current code and increment with a licensed coding reference.
- Maintain separate inventory and charge entries for each product.
- Review substitutions with the clinical and billing leads before use.
A worked example
A practice adds a second toxin brand. Copying the first product’s charge entry can carry over the wrong unit increment even when the label looks familiar. Create a separate product row with code, increment, source date and reviewer; leave clinical dosing to the treating professional.
Illustrative workflow example; not a patient case or individualized recommendation.
Mistakes to avoid
- Using “Botox” as the inventory name for every toxin.
- Turning reimbursement units into equivalent clinical doses.
- Assuming this selected list includes every newly approved product.